ReviewMolecular neurobiology2026
Harnessing Regulatory T Cells to Modulate Acute Brain Injury: From Mechanisms to Therapy.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammation is a defining feature of acute brain injury such as acute ischemic stroke, traumatic brain injury, intracerebral hemorrhage, and subarachnoid hemorrhage, driven by complex immune interactions within the central nervous system (CNS). Among these, regulatory T cells (Tregs) have emerged as pivotal modulators that counteract the deleterious effects of effector T cell subsets, including Th1 and Th17 cells, which exacerbate blood-brain barrier (BBB) disruption, leukocyte infiltration, and glial activation. In contrast, Tregs exert immunosuppressive and tissue-reparative effects that promote neuroprotection, BBB integrity, and resolution of inflammation. This review examines the mechanistic roles of Tregs in modulating CNS-resident cells such as microglia, astrocytes, and endothelial cells, with emphasis on their capacity to suppress inflammation and support functional recovery. We also highlight emerging therapeutic strategies including low-dose interleukin-2 for selective Treg expansion, exosome-based immunomodulation, and chemokine-directed cell trafficking as promising avenues for clinical intervention. Finally, we discuss translational efforts to harness Tregs in acute neuroinflammatory disease, highlighting their potential as key targets for future therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.